Use access key #2 to skip to page content.

Stock eligibility



December 12, 2011 – Comments (4) | RELATED TICKERS: SYN

Does anyone have a clear understanding of the current eligibility rules?

The last I heard, the median volume of the stock had to be greater than $50000 over the last 90 days.

Adeona (AEN) has had a volume greater than $50000 for more than 50 of the last 90 days, which means that the median value has to be greater than $50000, but the stock is still not eligible.

I contacted CAPS but no response. Am I missing something here?

4 Comments – Post Your Own

#1) On December 12, 2011 at 6:50 PM, constructive (99.97) wrote:

"You may only rate stocks that have an average three month volume in excess of $50,000, a previous days volume above $50,000 and a current share price greater than 50 cents. (Note: If you have rated a stock that falls below this threshold, you do not have to end your pick.)

Currently, players may rate stocks in the NYSE, NASDAQ, and AMEX, as well as "over the counter" or "pink sheet" stocks, as long as they meet the minimum average volume."

Avg. Daily Vol. (Mil) 0.23Glancing at Google Finance, it looks like AEN averaged around $15K per day before November 21 and has averaged about $80K per day since then?  Looks below $50K 90 day average to me.

Report this comment
#2) On December 26, 2011 at 9:19 AM, siri22 (< 20) wrote:

then abio should qualify

Report this comment
#3) On January 11, 2012 at 10:33 AM, goldminingXpert (28.84) wrote:

Off-topic question ... I am wondering if you have updated thoughts on MITI. I know you red-thumbed it in 2008 and it has inexplicably (in my opinion) surged back up to within a hair of its all-time high. Has something material changed?

Report this comment
#4) On January 20, 2012 at 1:12 PM, zzlangerhans (99.80) wrote:

Sorry GMX, don't keep my eye on the blogs much. Clearly I was wrong about Micromet from a stock perspective. Three and a half years later the market cap has increased about 400% based on the potential of blinatumomab in ALL and B cell lymphoma. The company has gotten away with fairly heavy dilution and slow progress in clinical trials without any retracements large enough to let me close my red thumb.

I don't follow Micromet very closely because I can't play them on CAPS and I'm not well-versed in hematologic malignancies. The market cap of 750M does seem excessive and the recent upward momentum unjustified. However, renewed careful analysis of blinatumomab's potential including the possibility of accelerated approval would be necessary before making any firm judgments. Seattle Genetics and Pharmacyclics have done even better that Micromet with pipelines directed against hematologic malignancy.

Report this comment

Featured Broker Partners